Literature DB >> 22292365

[Comparative study on four kinds of assessment methods of post-marketing safety of Danhong injection].

Xuelin Li1, Jinfa Tang, Fei Meng, Chunxiao Li, Yanming Xie.   

Abstract

OBJECTIVE: To study the adverse reaction of Danhong injection with four kinds of methods, central monitoring method, chart review method, literature study method and spontaneous reporting method, and to compare the differences between them, explore an appropriate method to carry out post-marketing safety evaluation of traditional Chinese medicine injection.
METHOD: Set down the adverse reactions' questionnaire of four kinds of methods, central monitoring method, chart review method, literature study method and collect the information on adverse reactions in a certain period. Danhong injection adverse reaction information from Henan Province spontaneous reporting system was collected with spontaneous reporting method. Carry on data summary and descriptive analysis. RESULT: Study the adverse reaction of Danhong injection with four methods of central monitoring method, chart review method, literature study method and spontaneous reporting method, the rates of adverse events were 0.993%, 0.336%, 0.515%, 0.067%, respectively. Cyanosis, arrhythmia, hypotension, sweating, erythema, hemorrhage dermatitis, rash, irritability, bleeding gums, toothache, tinnitus, asthma, elevated aminotransferases, constipation, pain are new discovered adverse reactions.
CONCLUSION: The central monitoring method is the appropriate method to carry out post-marketing safety evaluation of traditional Chinese medicine injection, which could objectively reflect the real world of clinical usage.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22292365

Source DB:  PubMed          Journal:  Zhongguo Zhong Yao Za Zhi        ISSN: 1001-5302


  1 in total

1.  Postmarketing Safety Surveillance and Reevaluation of Danhong Injection: Clinical Study of 30888 Cases.

Authors:  Xue-Lin Li; Jin-Fa Tang; Wei-Xia Li; Chun-Xiao Li; Tao Zhao; Bu-Chang Zhao; Yong Wang; Hui Zhang; Xiao-Fei Chen; Tao Xu; Ming-Jun Zhu
Journal:  Evid Based Complement Alternat Med       Date:  2015-10-05       Impact factor: 2.629

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.